Recent Quotes (30 days)

You have no recent quotes
chg | %

Oncolytics Biotech Inc.  

(Public, TSE:ONC)   Watch this stock  
Find more results for ONC
+0.030 (5.45%)
Delayed:   12:02PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.56 - 0.61
52 week 0.44 - 1.74
Open 0.60
Vol / Avg. 32,700.00/86,103.00
Mkt cap 68.43M
P/E     -
Div/yield     -
EPS -0.16
Shares 117.98M
Beta 2.06
Inst. own     -
Nov 4, 2015
Q3 2015 Oncolytics Biotech Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Oncolytics Biotech Inc at Robert W Baird and Co Health Care Conference
Aug 13, 2015
Oncolytics Biotech Inc at Canaccord Genuity Growth Conference
Aug 6, 2015
Q2 2015 Oncolytics Biotech Inc Earnings Release

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.79% -82.00%
Return on average equity -53.90% -103.35%
Employees 22 -
CDP Score - -


Suite 210, 1167 Kensington Crescent NW
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links


Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. Its clinical trial program includes human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB), a Barbados company, and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncol

Officers and directors

Bradley G. Thompson Ph.D. Executive Chairman of the Board, President, Chief Executive Officer
Kirk J. Look Chief Financial Officer
Matthew C. Coffey Ph.D. Chief Operating Officer, Director
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Alan J. Tuchman M.D. Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Age: 68
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Robert B. Schultz Lead Independent Director
Angela Frances Holtham Director
Edwin Levy Ph.D. Director
J. Mark Lievonen Director